F. Perrone

发表

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

Gaetano Rocco, Vittorio Gebbia, Simona Signoriello, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

N. Normanno, G. de Feo, J. Bryce, 2009, The oncologist.

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

Paolo A Ascierto, P. Ascierto, S. Pignata, 2014, Journal of Translational Medicine.

Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome

X. Terra, F. Perrone, F. Vidal, 2021, Journal of personalized medicine.

Statistical design in phase II clinical trials and its application in breast cancer.

G. Signoriello, G. Di Lorenzo, M. Di Maio, 2003, The Lancet. Oncology.

Cost of Insurance Policies for Investigator-Initiated Cancer Clinical Trials in Italy

R. Labianca, V. Torri, M. Marangolo, 2005, Tumori.

TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol

G. Botti, P. Ascierto, M. Massari, 2020, Contemporary Clinical Trials.

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

B. Daniele, C. Gallo, F. Perrone, 2008 .

Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (> or = 70 years of age)?

I. Fentiman, S. Monfardini, F. Perrone, 1997, European journal of cancer.

Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

D. Katsaros, F. Ghezzi, S. Pignata, 2007, Oncology.

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

S. Pignata, R. Biamonte, M. Valerio, 2006, BMC Cancer.

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.

G. Botti, N. Normanno, G. de Feo, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Is human hepatocellular carcinoma a hormone-responsive tumor?

S. Pignata, B. Daniele, M. Di Maio, 2008, World journal of gastroenterology.

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

N. Hanna, C. Gridelli, J. Heymach, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.

C. Gridelli, Chun-Ming Tsai, M. Di Maio, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

J. Cuzick, J. Bergh, R. Peto, 2022, The Lancet. Oncology.

Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.

G. D'aiuto, G. Botti, G. de Feo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.

M. Rinaldo, G. D'aiuto, G. Botti, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should Adjuvant Chemotherapy be used to Treat Breast Cancer in Elderly Patients (≥ 70 Years of Age)? Pro

F. Perrone, E. De Maio, 2002, Tumori.

The Standard of Care Definitions on COVID-19 Pharmacological Clinical Trials: A Systematic Review

L. Amato, M. Davoli, F. Perrone, 2021, Frontiers in Pharmacology.

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

C. Gridelli, F. Ciardiello, C. D. Della Corte, 2021, BMC cancer.

Ethics in Oncology: Principles and Responsibilities Declared in the Italian Ragusa Statement

R. Labianca, F. di Costanzo, P. Marchetti, 2016, Tumori.

A predictive index of axillary nodal involvement in operable breast cancer.

P. Delrio, S. de Placido, A. Bianco, 1996, British Journal of Cancer.

Assessing clinical efficacy of drugs in cancer patients: are we on the right track?

C. Gallo, F. Perrone, 2011 .

Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.

M. Di Maio, F. Perrone, A. Mariniello, 2021, European journal of cancer.

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology

G. Botti, P. Ascierto, S. Pignata, 2019, PloS one.

Denosumab in early breast cancer: negative data and a call to action.

F. Perrone, A. Gravina, 2019, The Lancet. Oncology.

Quality of Life in elderly patients with cancer

M. Di Maio, F. Perrone, 2003, Health and quality of life outcomes.

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.

G. Chiappetta, S. Pignata, L. De Cecco, 2016, The Lancet. Oncology.

The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy.

C. Gridelli, F. Ciardiello, J. Bryce, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)

C. Porta, S. Novello, V. Adamo, 2022, Tumori.

Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.

G. Scagliotti, S. Novello, C. Sonetto, 2019, Lung cancer.

A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan

C. Gallo, M. Piccirillo, F. Perrone, 2020, Contemporary Clinical Trials Communications.

Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

Maria Paola Costi, N. Normanno, S. Pignata, 2022, International Journal of Gynecological Cancer.

Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.

S. Barni, C. Gridelli, F. de Marinis, 2007, Critical reviews in oncology/hematology.

EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer

H. Groen, S. Michiels, C. Faivre-Finn, 2021, Translational lung cancer research.

Treatment of small cell lung cancer.

N. Normanno, M. Di Maio, C. Sandomenico, 2014, Critical reviews in oncology/hematology.

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer

I. Vergote, S. Pignata, J. Bryce, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.

I. Vergote, S. Pignata, J. Bryce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial.

C. Gridelli, L. Frontini, B. Daniele, 2009, Lung cancer.

Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer

C. Gridelli, C. Sandomenico, M. Piccirillo, 2012 .

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.

C. Gridelli, L. Cavanna, F. de Marinis, 2013, Lung cancer.

An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH tri

C. Gridelli, F. Ciardiello, C. Gallo, 2008, Clinical lung cancer.

COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?

G. Beretta, A. Russo, R. Chiari, 2021, ESMO Open.

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

G. Botti, D. Galetta, L. Crinò, 2019, Cancers.

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer

N. Normanno, G. Esposito, C. Sandomenico, 2020, Exploration of targeted anti-tumor therapy.

Bevacizumab in non small cell lung cancer: development, current status and issues.

N. Normanno, M. Di Maio, C. Sandomenico, 2012, Current medicinal chemistry.

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience

M. Rinaldo, G. D'aiuto, C. Pacilio, 2005, BMC Cancer.

Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study

S. Pignata, V. Canzonieri, G. Scognamiglio, 2021, Cancers.

Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials

N. Normanno, A. Budillon, M. Di Maio, 2005, Current opinion in oncology.

Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.

N. Normanno, R. Bianco, C. Sandomenico, 2016, Critical reviews in oncology/hematology.

Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.

A. Rossi, C. Gridelli, L. Cavanna, 2014, Clinical lung cancer.

Rationale and Design of MILES-3 and MILES-4 Studies : Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non e Small-Cell Lung Cancer

A. Rossi, C. Gridelli, L. Cavanna, 2022 .

Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer.

C. Gallo, A. Morabito, F. Perrone, 1995, Oncology.

Targeted therapies: Role of sorafenib in HCC patients with compromised liver function

B. Daniele, F. Perrone, M. Maio, 2009, Nature Reviews Clinical Oncology.

Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.

R. Labianca, L. Cavanna, G. Beretta, 2021, European journal of cancer.

Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study.

A. Rossi, C. Gridelli, M. Di Maio, 2002, Lung cancer.

The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.

C. Gridelli, G. Signoriello, A. Morabito, 2008, Lung cancer.

Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies.

C. Gridelli, V. Lorusso, C. Gallo, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES).

C. Gridelli, M. Di Maio, C. Gallo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

D. Katsaros, A. Gadducci, A. Lissoni, 2021, International Journal of Gynecological Cancer.

Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

M. Campiglio, N. Normanno, M. Di Maio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials.

D. Cella, N. Aaronson, M. Vignetti, 2021, Journal of the National Cancer Institute.

Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018.

G. Scagliotti, S. Novello, C. Sonetto, 2019, Clinical genitourinary cancer.

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group

S. Pignata, V. Zagonel, G. Scambia, 2007, British Journal of Cancer.

The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018

P. Ascierto, A. Testori, H. Tawbi, 2019, Journal of Translational Medicine.

Surrogate endpoints: can size of effect mitigate perplexity?

F. Perrone, 2013, The Lancet. Oncology.

Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer

G. D'aiuto, G. Botti, J. Russo, 2006, Clinical Cancer Research.

Chemotherapy for Metastatic Breast Cancer Patients Who Received Adjuvant Anthracyclines (An Overview)

J. Bryce, M. Piccirillo, A. Morabito, 2008 .

Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast

G. D'aiuto, G. Botti, F. Nuzzo, 2002, Cancer.

Zoledronic acid in early-stage breast cancer.

N. Normanno, A. De Luca, F. Perrone, 2011, The Lancet. Oncology.

Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence

A. Vecchione, N. Normanno, A. De Luca, 2011, Expert review of anticancer therapy.

Vandetanib as a potential treatment for breast cancer

D. Frezzetti, N. Normanno, A. De Luca, 2014, Expert opinion on investigational drugs.

Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy

M. Cantile, S. Pignata, M. Di Maio, 2016, Analytical cellular pathology.

Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.

M. Lambertini, F. Perrone, L. Del Mastro, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic evaluation of capecitabine in breast cancer

N. Normanno, A. De Luca, A. D'alessio, 2013, Expert opinion on drug metabolism & toxicology.

Current Controversies in Cancer Should Adjuvant Chemotherapy be used to Treat Breast Cancer in Elderly Patients (2 70 years of age)

I. Fentiman, S. Monfardini, F. Perrone, 1997 .

Patient-reported outcomes in the evaluation of toxicity of anticancer treatment

E. Basch, J. Bryce, F. Perrone, 2022 .

Diagnostic Gleason score and castration- resistant prostate cancer

F. Perrone, M. Maio, 2016 .

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

S. Pignata, G. Signoriello, G. Scambia, 2006, BMC Cancer.

Staging for liver cancer.

B. Daniele, F. Perrone, 2005, Clinics in liver disease.

Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement

G. Beretta, V. Zagonel, F. Perrone, 2022, ESMO Open.

Early Access in Oncology: Why Is It Needed?

G. Apolone, A. Ardizzoni, M. Maio, 2019, Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish.

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol

F. Izzo, P. Delrio, G. Botti, 2020, Therapeutic advances in medical oncology.

Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

D. Katsaros, A. Gadducci, A. Lissoni, 2021, International Journal of Gynecological Cancer.

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.

S. Pignata, F. Cognetti, G. Scambia, 2019, Gynecologic oncology.

Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.

S. Pignata, C. Sessa, I. Ray-Coquard, 2018 .

A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomy.

M. Di Maio, G. Rocco, F. Perrone, 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab

A. Gadducci, S. Pignata, V. Canzonieri, 2022, Diagnostics.

Prognostic Value of CD40 in Adult Soft Tissue Sarcomas

G. Botti, P. Ascierto, F. Fazioli, 2004, Clinical Cancer Research.

Prognostic Value of CD 40 in Adult Soft Tissue Sarcomas

G. Botti, P. Ascierto, F. Fazioli, 2004 .

Vandetanib: An overview of its clinical development in NSCLC and other tumors.

N. Normanno, J. Bryce, M. Di Maio, 2010, Drugs of today.

PCNI4 ALCEA (ADVANCED LUNG CANCER ECONOMIC ASSESSMENT)

F. Perrone, C. Negrini, F. Salvati, 2004 .

Cost of non-small cell lung cancer in Italy. Results of the longitudinal study ALCEA (Advanced Lung Cancer Economic Assessment).

F. Perrone, G. Benelli, C. Negrini, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).

J. Cuzick, J. Forbes, M. Dowsett, 2014 .

Second medical opinion in oncological setting.

G. Beretta, P. Marchetti, V. Zagonel, 2021, Critical reviews in oncology/hematology.

Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach.

S. Riva, M. Di Maio, C. Gallo, 2019, Journal of oncology practice.

Endocrine Factors in the Outcome of Systemic Adjuvant Therapy of Early Breast Cancer a

A. Bianco, C. Gallo, F. Perrone, 1993, Annals of the New York Academy of Sciences.

Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.

S. de Placido, A. Bianco, C. Gallo, 1990, British Journal of Cancer.

Pharmacokinetic evaluation of zoledronic acid

N. Normanno, A. De Luca, M. Maiello, 2011, Expert opinion on drug metabolism & toxicology.

G. Botti, N. Normanno, C. Pacilio, 2022 .

A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice.

M. Di Maio, F. Perrone, L. Del Mastro, 2017, JAMA oncology.

The opportunity of patient-journey studies for academic clinical research in oncology

C. Gallo, M. Piccirillo, F. Perrone, 2021, BMJ Open.

Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?

C. Gridelli, C. Gallo, F. Perrone, 2006, Nature Clinical Practice Oncology.

The Effects of Patient-Reported Outcome Screening on the Survival of People with Cancer: A Systematic Review and Meta-Analysis

F. Perrone, C. Caminiti, F. Diodati, 2022, Cancers.

A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy. The PRECOL trial

Giovanni Battista Rossi, M. Di Maio, C. Gallo, 2022, Frontiers in Medicine.

Reply to P. Baldo et al.

M. Di Maio, C. Gallo, F. Perrone, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subgroup Analysis: Refining a Positive Result or Trying to Rescue a Negative One?

M. Di Maio, F. Perrone, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients

S. Pignata, L. Portella, G. Scognamiglio, 2022, Cancers.

The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020

R. Sullivan, P. Ascierto, B. Fox, 2021, Journal of Translational Medicine.

Hepatocellular Carcinoma: Systemic Treatments

S. Pignata, B. Daniele, M. Di Maio, 2002, Journal of clinical gastroenterology.

Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system

C. Porta, L. Frontini, J. Bryce, 2021, BMJ Open.

Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?

C. Gridelli, N. Normanno, A. De Luca, 2004, Anticancer research.

Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.

C. Gridelli, L. Cavanna, M. Mencoboni, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.

A. Rossi, C. Gridelli, M. Mencoboni, 2010, Lung cancer.

Hormonal Treatment of Human Hepatocellular Carcinoma

M. Di Maio, C. Gallo, A. Morabito, 2006, Annals of the New York Academy of Sciences.

Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.

C. Gridelli, K. Kelly, F. Shepherd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.

C. Gridelli, A. Bezjak, L. Seymour, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

A. Rossi, C. Gridelli, D. Galetta, 2003, Journal of the National Cancer Institute.

First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients: A Phase II Study

A. Rossi, S. Pignata, B. Daniele, 2003, Journal of clinical gastroenterology.

First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients

A. Rossi, S. Pignata, C. Gallo, 2003 .

Gemcitabine Plus Vinore lb ine Compared With Cisplat in Plus Vinore lb ine or Cisplat in Plus Gemci tabine for Advanced Non – Smal l-Cel l Lung Cancer : A Phase III Tria

A. Bezjak, L. Seymour, F. Shepherd, 2003 .

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

S. Barni, G. Botti, G. Botti, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

G. D'aiuto, G. Signoriello, C. Pacilio, 2008, Critical reviews in oncology/hematology.

Prognostic significance of combined analysis of ZAP‐70 and CD38 in chronic lymphocytic leukemia

P. Chiusolo, S. Deaglio, F. Malavasi, 2007, American journal of hematology.

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

A. Rossi, C. Gridelli, W. Qian, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Angiogenesis Inhibitors in NSCLC

N. Normanno, C. Sandomenico, M. Piccirillo, 2017, International journal of molecular sciences.

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

F. Izzo, M. Rinaldi, S. Pignata, 1998, Hepatology.

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.

A. Rossi, C. Gridelli, F. de Marinis, 2016, Clinical lung cancer.

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

R. Labianca, L. Cavanna, F. di Costanzo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermediate dose recombinant interferon‐α as second‐line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon

P. Ascierto, G. Palmieri, G. Castello, 2000, Cancer.

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

S. Pignata, R. Biamonte, M. Valerio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR Mutations

C. Sandomenico, M. Piccirillo, G. Daniele, 2019, Oncogenomics.

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives

R. Franco, N. Normanno, M. Di Maio, 2013, Expert review of anticancer therapy.

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

D. Katsaros, B. Weber, S. Pignata, 2014, The Lancet. Oncology.

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients

A. Rossi, C. Gridelli, M. Tsao, 2017, Oncotarget.

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

M. Stockler, K. Ding, F. Shepherd, 2014 .

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.

A. Gadducci, S. Pignata, C. Sessa, 2021, The Lancet. Oncology.

Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80)

Bellia Mario, F. Izzo, P. Vallone, 2000 .

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

A. Giordano, N. Normanno, A. De Luca, 2005, Endocrine-related cancer.

First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.

C. Pacilio, C. Gallo, M. Piccirillo, 2007, The oncologist.

Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer

A. Bianco, C. Gallo, F. Perrone, 1990, Breast Cancer Research and Treatment.

A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.

A. Rossi, C. Gridelli, L. Cavanna, 2017, Lung cancer.

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

N. Normanno, M. Di Maio, A. Morabito, 2006, The oncologist.

Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer

S. Iacobelli, C. Gridelli, A. Russo, 2004, Cancer Chemotherapy and Pharmacology.

Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).

C. Gridelli, D. Coyle, L. Seymour, 2013, Lung cancer.

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

C. Gridelli, E. Felip, F. de Marinis, 2015, Clinical lung cancer.

New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development

N. Normanno, M. Di Maio, M. Piccirillo, 2010, Expert opinion on investigational drugs.

Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials.

A. Rossi, C. Gridelli, A. Ceribelli, 2012, Lung cancer.

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

A. Brandes, S. Pignata, M. Valerio, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP).

F. Izzo, S. Pignata, B. Daniele, 2006, Critical reviews in oncology/hematology.

The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer.

S. Pignata, M. Di Maio, F. Perrone, 2006, Frontiers in bioscience : a journal and virtual library.

Prognostic Value of Serum Biological Markers in Patients with Hepatocellular Carcinoma 1

F. Izzo, S. Pignata, B. Daniele, 2001 .

Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.

G. Luporini, A. Rossi, C. Gridelli, 1999, Journal of the National Cancer Institute.

Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease

G. De Michele, A. Filla, G. Campanella, 1996, Neurology.

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

A. Bianco, C. Gallo, A. Morabito, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes?

A. Bianco, A. Bianco, C. Gallo, 1996, European journal of cancer.

The prognostic value of lymphatic and blood vessel invasion in operable breast cancer

A. Bianco, C. Gallo, A. Morabito, 1995, Cancer.

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

R. Lauria, S. De Placido, F. Perrone, 1995, British Journal of Cancer.

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.

S. De Placido, E. Matano, A. Bianco, 1991, British Journal of Cancer.

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review

V. Adamo, G. Curigliano, F. Puglisi, 2022, Cancers.

BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function

S. Barni, F. Izzo, L. Cavanna, 2021, Hepatoma Research.

Clinical Trials and Methodology of Cancer Research

M. Di Maio, F. Perrone, 2021, Practical Medical Oncology Textbook.

Gefitinib in Non Small Cell Lung Cancer

Gaetano Rocco, N. Normanno, J. Bryce, 2011, Journal of biomedicine & biotechnology.

Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….

M. Di Maio, C. Sandomenico, M. Piccirillo, 2014, Current pharmaceutical design.

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer

A. Rossi, C. Gridelli, M. Tsao, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.

A. Rossi, C. Gridelli, M. Tsao, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Target-based therapies in breast cancer: current status and future perspectives.

N. Normanno, A. De Luca, M. Maiello, 2009, Endocrine-related cancer.

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

E. Basch, J. Bryce, F. Perrone, 2016, Nature Reviews Clinical Oncology.

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.

F. Cappuzzo, C. Gridelli, R. Stahel, 2012, Lung cancer.

First-line systemic therapy for metastatic breast cancer and management of pleural effusion.

A. Bianco, F. Perrone, C. Carlomagno, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Giampietro Gasparini, Giuseppe Colucci, Giovanni Scambia, 2006, BMC cancer.

Predictivity of clinical, laboratory and imaging findings in diagnostic definition of palpable thyroid nodules. A multicenter prospective study

M. Pelizzo, F. Fulciniti, G. Perigli, 2018, Endocrine.

A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system

L. Frontini, J. Bryce, S. Riva, 2020, Supportive Care in Cancer.

Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.

A. Rossi, C. Gridelli, N. Normanno, 2014, Lung cancer.

Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma

F. Fazioli, M. Di Maio, V. Gebbia, 2016, Sarcoma.

Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.

P. Ascierto, A. Cossu, G. Palmieri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

A. Rossi, C. Gridelli, Keunchil Park, 2014, The Lancet. Oncology.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

M. Nicoloso, S. Pignata, G. de Matteis, 2023, The Lancet. Oncology.

Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey

R. Labianca, F. D. De Braud, F. Roila, 2009, Tumori.

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.

A. Brandes, S. Pignata, G. Scambia, 2015, The Lancet. Oncology.

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

S. Pignata, V. Canzonieri, C. Casanova, 2022, British Journal of Cancer.

Real-World Evidence in Oncology: Opportunities and Limitations.

P. Conte, M. Di Maio, F. Perrone, 2019, The oncologist.

Tackling off-label use of anticancer drugs.

R. Labianca, F. D. De Braud, F. Roila, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic V alue o f C irculating M elanoma C ells D etected b y Reverse T ranscriptase-Po lymerase C hain R eaction

P. Ascierto, A. Cossu, G. Palmieri, 2003 .

Vinorelbine for non-small cell lung cancer

J. Bryce, M. Di Maio, M. Piccirillo, 2010, Expert opinion on drug safety.

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.

S. Barni, N. Normanno, C. Pacilio, 2019, European journal of cancer.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

G. Arpino, A. Russo, F. Montemurro, 2018, The Lancet. Oncology.

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

P. Ascierto, S. Pignata, B. Daniele, 2014, Journal of Translational Medicine.

Trans‐arterial chemo‐embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database

T. Yau, R. Poon, M. Di Maio, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience

S. Pignata, L. De Cecco, S. Canevari, 2020, Cells.

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

P. Tagliaferri, B. Kopf, N. Normanno, 2019, Gynecologic oncology.

A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer

S. Pignata, A. Bianco, A. Morabito, 1999, Oncology.

Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors

G. Banna, F. Puglisi, M. Di Maio, 2013, Anti-cancer drugs.

Chemotherapy with Mitomycin C and Vinblastine in Pretreated Metastatic Breast Cancer

C. Gridelli, A. Bianco, F. Nuzzo, 1993, Tumori.

Abstract GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials

J. Bergh, R. Peto, M. Gnant, 2022, Cancer Research.

Mitomycin C and Mitoxantrone in Anthracycline‐Pretreated Advanced Breast Cancer Patients: A Phase II Study

C. Gridelli, A. Bianco, F. Perrone, 1994, American journal of clinical oncology.

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

M. Stockler, L. Seymour, M. Tsao, 2014, The Lancet. Oncology.

Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials

M. Piccirillo, F. Perrone, P. Gargiulo, 2021, Life.

Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.

C. Gridelli, S. Novello, V. Adamo, 2001, Lung cancer.

Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM)

E. Vasile, V. Torri, P. Bruzzi, 2016, ESMO Open.

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

S. Barni, R. Labianca, G. Luporini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial

A. Vecchione, A. Rossi, C. Gridelli, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.

C. Gridelli, C. Gallo, F. Perrone, 2002, Journal of the National Cancer Institute.

Methodological issues of clinical research with EGFR inhibitors

N. Normanno, M. Piccirillo, A. Morabito, 2007 .

Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

M. Campiglio, S. Ménard, N. Normanno, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy

J. Bryce, M. Piccirillo, A. Morabito, 2009 .

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

M. Rinaldo, G. D'aiuto, G. Botti, 2011, BMC Cancer.

Cancer in Transgender and Gender-Diverse Persons: A Review.

N. Scout, M. Schabath, R. Miceli, 2023, JAMA oncology.

Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer.

G. Di Lorenzo, M. Di Maio, C. Gallo, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

N. Hanna, C. Gridelli, F. Shepherd, 2010, Lung cancer.

Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature.

F. Fiore, S. Pignata, B. Daniele, 2003, Critical reviews in oncology/hematology.

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)

P. Delrio, G. Botti, E. Di Gennaro, 2014, BMC Cancer.

Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab

F. Izzo, G. Nasti, F. Tatangelo, 2013, The Journal of Nuclear Medicine.

Salvage Chemotherapy with Ccnu and Methotrexate for Small Cell Lung Cancer Resistant to Cav/Pe Alternating Chemotherapy

C. Gridelli, A. Bianco, F. Perrone, 1991, Tumori.

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.

A. Rossi, C. Gridelli, L. Cavanna, 2019, Lung cancer.

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

A. Russo, B. Vincenzi, M. Silletta, 2015, PloS one.

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.

C. Gridelli, V. Georgoulias, E. Smit, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study

L. Marandino, M. Di Maio, F. Perrone, 2023, BMJ Oncology.

The First Breast Cancer Screening Program in Southern Italy: Preliminary Results from Three Municipalities of the Naples Province

P. Delrio, A. Sodano, A. Bianco, 1995, Tumori.

Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial.

C. Gridelli, L. Cavanna, F. de Marinis, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integrated therapeutic approaches in the treatment of locally advanced non-small cell lung cancer.

David R. Jones, M. Di Maio, C. Sandomenico, 2013, Anti-cancer agents in medicinal chemistry.

Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018.

G. Scagliotti, S. Novello, C. Sonetto, 2020, Critical reviews in oncology/hematology.

Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.

N. Normanno, S. Pignata, A. De Luca, 2002, International journal of oncology.

Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma: A Cancer of the Liver Italian Program (CLIP 08) Retrospective Case–Control Study

F. Izzo, P. Vallone, F. Fiore, 2003, Journal of clinical gastroenterology.

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.

A. Rossi, C. Gridelli, A. Ceribelli, 2007, The Lancet. Oncology.

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

C. Gridelli, F. Ciardiello, C. D. Della Corte, 2005, BMC Cancer.

Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).

V. Zagonel, R. Rosso, M. Venturini, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

B. Daniele, G. Signoriello, M. Di Maio, 2012, Cancers.

Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer

C. Gridelli, N. Normanno, F. Ciardiello, 2005, Journal of cellular physiology.

Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma

S. Pignata, B. Daniele, G. Signoriello, 2006, BMC Cancer.

Adjuvant ovarian suppression in premenopausal breast cancer.

F. Montemurro, F. Perrone, Francesco Perrone, 2015, The New England journal of medicine.

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

F. Montagnini, M. Giacomini, G. Innocenti, 2020, Journal of Translational Medicine.

Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy

B. Gyawali, F. Perrone, R. Da Cas, 2019, BMJ Open.

Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial

S. Pignata, G. Signoriello, F. Cognetti, 2008, Oncology.

The Judicial Path to European Constitutionalism: The Role of the National Judge in the Multi-Level Dialogue

F. Perrone, 2019, Judicial Power in a Globalized World.

New biological treatments for gynecological tumors: focus on angiogenesis

S. Pignata, J. Bryce, M. Di Maio, 2014, Expert opinion on biological therapy.

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

Antonella Petrillo, Vincenza Granata, Gerardo Botti, 2016, BMC Cancer.

Conventional chemotherapy of advanced pancreatic cancer.

G. Colucci, M. Di Maio, F. Perrone, 2012, Current Drug Targets.

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.

C. Gridelli, V. Georgoulias, E. Smit, 2010, European journal of cancer.

Exploratory research into cancer patients’ attitudes to clinical trials

F. Perrone, K. Oliver, Corina W Ramers-Verhoeven, 2014, Ecancermedicalscience.

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?

N. Normanno, A. De Luca, F. Perrone, 2020, EBioMedicine.

Reply to “Weekly paclitaxel in elderly breast cancer patients”, by C. Smorenburg et al. (Ann Oncol 2005; 16: 1979)

F. Perrone, L. Mastro, 2005 .

International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial.

C. Gridelli, F. Ciardiello, R. Wierzbicki, 2010 .

[Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy].

M. Di Maio, C. Gallo, F. Perrone, 2008, Tumori.

Methodological aspects of lung cancer clinical trials in the era of targeted agents.

C. Gridelli, M. Di Maio, C. Gallo, 2010, Lung cancer.

What is the future for cancer clinical trials?

F. Perrone, 2015, Future oncology.

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC

R. Franco, G. Chiappetta, S. Pignata, 2016, Oncotarget.

[Independent clinical research in oncology].

F. Perrone, 2004, I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.].

Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.

A. de Matteis, F. Perrone, E. Bria, 2005, Anticancer research.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

S. Pignata, A. Tomassetti, L. De Cecco, 2023, Journal of Experimental & Clinical Cancer Research.

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial

P. Ascierto, M. Massari, M. Costantini, 2020, medRxiv.

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.

S. Pignata, V. Zagonel, G. Scambia, 2008, Critical reviews in oncology/hematology.

Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

G. D'aiuto, G. Botti, G. Signoriello, 2007, BMC Cancer.

Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial

S. Pignata, B. Daniele, C. Gallo, 1998, The Lancet.

Tamoxifen in hepatocellular carcinoma

S. Pignata, B. Daniele, C. Gallo, 1998, The Lancet.

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.

G. Botti, N. Normanno, G. Esposito, 2012 .

into clinical practice for the treatment of patients with advanced NSCLC.

F. Perrone, 2011 .

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.

I. Floriani, S. Pignata, N. Colombo, 2017, Gynecologic oncology.

Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.

A. Fabi, L. Marandino, M. Di Maio, 2023, European journal of cancer.

Cetuximab (C) and gemcitabine (G) in elderly or adult PS2 advanced non small-cell lung cancer (NSCLC) patients (pts): The CALC1 randomised phase II trials

C. Gridelli, M. Mencoboni, F. Ciardiello, 2008 .

International Clinical Trials Day 2014—ancient and modern needs

F. Perrone, 2014, Ecancermedicalscience.

Cetuximab in non-small-cell lung cancer

N. Normanno, J. Bryce, M. Di Maio, 2012, Expert review of anticancer therapy.

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.

S. Pignata, D. Califano, C. Marchetti, 2023, Gynecologic oncology.

Skip pattern approach toward the early access of innovative anticancer drugs

G. Apolone, A. Ardizzoni, M. Maio, 2021, ESMO open.

Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma

Bernardino, A. Giorgio, A. Iannelli, 2000, Hepatology.

A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynec

D. Katsaros, B. Weber, G. Scambia, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018.

M. Sant, F. Perrone, P. Baili, 2022, The European journal of health economics : HEPAC : health economics in prevention and care.

Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol

L. Frontini, J. Bryce, S. Riva, 2019, BMJ Open.

Cetuximab in NSCLC: another trial needed.

F. Perrone, 2011, The Lancet. Oncology.

Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial

A. Rossi, C. Gridelli, S. Monfardini, 1998 .

Quality of Life in elderly patients with cancer

M. Di Maio, F. Perrone, 2003, Health and quality of life outcomes.

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer

E. Matano, A. Bianco, C. Gallo, 1991 .

Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix.

S. Pignata, C. Gallo, F. Perrone, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

S. Pignata, V. Canzonieri, C. Casanova, 2022, British Journal of Cancer.

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

C. Gridelli, A. Ceribelli, P. Mazzanti, 2004, British Journal of Cancer.

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

C. Gridelli, F. de Marinis, A. Ardizzoni, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab

A. Lissoni, S. Pignata, D. Califano, 2023, Clinical pharmacology and therapeutics.

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

A. Rossi, C. Gridelli, D. Galetta, 2003, Journal of the National Cancer Institute.

Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research

R. Labianca, L. Frontini, Antonio Pepe, 2015, Journal of Medical Ethics.

Time Spent for Activation of Non-Profit Studies in Oncology in Italy

G. de Matteis, J. Bryce, M. Di Maio, 2010, PLoS ONE.

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

S. Andreola, M. Pierotti, S. Pilotti, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer

F. Puglisi, S. Pignata, F. Perrone, 2022, JAMA network open.

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial

S. Pignata, B. Daniele, C. Gallo, 2001, Gut.

Early PET / CT Scan Is More Effective Than Response Evaluation Criteria In Solid Tumors in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab

F. Izzo, G. Nasti, F. Tatangelo, 2013 .

256OWEEKLY DOCETAXEL (WD) VS CMF AS ADJUVANT CHEMOTHERAPY FOR ELDERLY EARLY BREAST CANCER (EBC) PATIENTS (PTS): FINAL RESULTS FROM THE RANDOMISED PHASE 3 ELDA TRIAL.

S. Barni, B. Daniele, C. Pacilio, 2014, Annals of Oncology.

Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).

C. Gridelli, L. Cavanna, L. Seymour, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Is Gemcitabine plus Vinorelbine Active in Second-Line Chemotherapy of Metastatic Breast Cancer? A Single-Center Phase 2 Study

G. D'aiuto, C. Gridelli, M. Di Maio, 2003, Oncology.

Registrative trials of antiemetic drugs: arrival or starting point?

M. Di Maio, F. Perrone, 2009, The Lancet. Oncology.

Prognostic value of serum biological markers in patients with hepatocellular carcinoma.

F. Izzo, S. Pignata, B. Daniele, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.

C. Gridelli, L. Cavanna, F. de Marinis, 2013, Lung cancer.

Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial.

N. Normanno, B. Daniele, E. Maiello, 2020, Clinical colorectal cancer.

Pharmacokinetic evaluation of capecitabine in breast cancer

N. Normanno, A. De Luca, M. Piccirillo, 2013, Expert opinion on drug metabolism & toxicology.